In short
BDC-1001 is an innovative drug currently being studied in clinical trials for patients with HER2-positive cancers, particularly metastatic breast cancer and other solid tumors. This immune-stimulating antibody conjugate (ISAC) is designed to target HER2-expressing tumors and activate the body's immune system to fight cancer. The ongoing trials aim to evaluate its effectiveness both as a single agent and in combination with other cancer treatments.
At a glance
- Drug Name
- BDC-1001
- Drug Type
- Immune-stimulating antibody conjugate (ISAC)
- Target
- HER2-expressing tumors
- Administration
- Intravenous, every 2 weeks
- Cancer Types
- HER2-positive metastatic breast cancer, other HER2-positive solid tumors
- Trial Phases
- Phase 1/2 and Phase 2
- Combination Therapies
- Tested with pertuzumab and nivolumab
- Primary Outcomes
- Safety, tolerability, anti-tumor activity
- Secondary Outcomes
- Duration of response, disease control rate, progression-free survival, overall survival
What is BDC-1001?
BDC-1001 is a new type of cancer treatment currently being studied in clinical trials. It belongs to a class of drugs called immune-stimulating antibody conjugates (ISACs). This innovative medication is designed to target and treat cancers that express high levels of a protein called HER2 (human epidermal growth factor receptor 2).
How Does BDC-1001 Work?
BDC-1001 works in a unique way to fight cancer:
- Targeting cancer cells: It contains a part that's similar to a drug called trastuzumab, which specifically attaches to HER2 proteins on cancer cells.
- Activating the immune system: BDC-1001 also carries a substance that activates special receptors called TLR7/8. This helps to "wake up" the body's immune system.
- Destroying cancer: By combining these two actions, BDC-1001 aims to help the body's own immune system recognize and destroy HER2-positive cancer cells more effectively.
What Conditions Does BDC-1001 Treat?
BDC-1001 is being studied for the treatment of several types of HER2-positive cancers, including:
- Metastatic breast cancer (cancer that has spread beyond the breast)
- Colorectal cancer (cancer of the colon or rectum)
- Gastroesophageal cancer (cancer of the stomach or esophagus)
- Endometrial cancer (cancer of the uterus lining)
- Other solid tumors that express HER2
Current Clinical Trials
There are currently two main clinical trials studying BDC-1001:
- Phase 2 trial for metastatic breast cancer: This study is testing BDC-1001 alone and in combination with another drug called pertuzumab in patients with HER2-positive metastatic breast cancer who have previously been treated with a drug called trastuzumab deruxtecan (Enhertu®).
- Phase 1/2 trial for various HER2-positive cancers: This study is looking at BDC-1001 alone and in combination with a drug called nivolumab (Opdivo®) in patients with different types of advanced HER2-positive cancers.
Potential Benefits
Researchers are studying BDC-1001 to see if it can provide benefits such as:
- Shrinking tumors or slowing their growth
- Improving survival rates
- Offering a new treatment option for patients who have already tried other therapies
- Potentially working better when combined with other cancer drugs
Safety and Side Effects
As BDC-1001 is still in clinical trials, its full safety profile is not yet known. The ongoing studies are carefully monitoring patients for:
- Side effects (called adverse events)
- Serious side effects
- Immune-related side effects
- How well patients tolerate different doses of the drug
It's important to note that all potential side effects will be thoroughly evaluated before the drug can be approved for general use.
Combination Therapy
BDC-1001 is being studied both as a single agent and in combination with other cancer drugs:
- With pertuzumab: Pertuzumab (also known as Perjeta®) is another drug that targets HER2. It works by preventing HER2 from partnering with other proteins, which can slow down cancer growth.
- With nivolumab: Nivolumab (also known as Opdivo®) is a type of immunotherapy that helps the body's immune system attack cancer cells.
These combinations are being tested to see if they can improve the effectiveness of treatment compared to using BDC-1001 alone.